Corinne Savill
Corporate Officer/Principal chez CULLINAN THERAPEUTICS, INC.
Fortune : 4 M $ au 30/04/2024
Provenance du réseau au premier degré de Corinne Savill
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.
31
| Subsidiary | Pharmaceuticals: Major | 31 |
| Public Company | Pharmaceuticals: Major | 23 | |
| Public Company | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Corinne Savill via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Founder Consultant / Advisor Private Equity Investor Private Equity Investor Director of Finance/CFO Private Equity Investor Consultant / Advisor | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal Compliance Officer Corporate Officer/Principal Human Resources Officer | |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal Compliance Officer General Counsel | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Public Communications Contact General Counsel | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman Director/Board Member Founder Chairman | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chairman | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| CAREDX, INC | Medical Specialties | Director/Board Member Director/Board Member Director of Finance/CFO | |
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Biotechnology | Corporate Officer/Principal Compliance Officer | |
| MEDIGENE AG | Biotechnology | Director/Board Member Director/Board Member | |
Clinical Ink, Inc.
 Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Internet Software/Services | Director/Board Member Director/Board Member | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Founder | |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| University of Leicester | College/University | Undergraduate Degree Undergraduate Degree | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin | |
Circassia Ltd.
 Circassia Ltd. Pharmaceuticals: OtherHealth Technology Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Novartis Vaccines & Diagnostics, Inc.
 Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | President Director of Finance/CFO | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Director of Finance/CFO | |
| Stanford University | College/University | Corporate Officer/Principal Undergraduate Degree | |
Sandoz International GmbH
 Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Pharmaceuticals: Generic | Corporate Officer/Principal General Counsel | |
| LONZA GROUP AG | Pharmaceuticals: Major | Director/Board Member Human Resources Officer | |
| BAYER AG | Pharmaceuticals: Major | Director/Board Member Sales & Marketing | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO President | |
| University College London | College/University | Undergraduate Degree Doctorate Degree | |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Biotechnology | Director/Board Member Chief Executive Officer | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Wisconsin | College/University | Graduate Degree Doctorate Degree | |
| TESARO INC | Pharmaceuticals: Major | Human Resources Officer Corporate Officer/Principal | |
| CELGENE | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| CARDAX, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Fordham University School of Law | College/University | Graduate Degree Graduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ALCON INC. | Medical Specialties | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| University of Basel | College/University | Doctorate Degree Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Corporate Officer/Principal | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 35 |
| Suisse | 7 |
| Allemagne | 5 |
| Royaume-Uni | 5 |
| Suède | 2 |
Sectorielle
| Health Technology | 34 |
| Consumer Services | 11 |
| Finance | 5 |
| Health Services | 2 |
| Technology Services | 2 |
Opérationnelle
| Director/Board Member | 238 |
| Corporate Officer/Principal | 137 |
| Independent Dir/Board Member | 64 |
| Director of Finance/CFO | 49 |
| Chief Tech/Sci/R&D Officer | 36 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| George Bickerstaff | 37 |
| Thomas Ebeling | 33 |
| Owen Hughes | 23 |
| Anthony Adam Rosenberg | 23 |
| Stephen Webster | 23 |
| James Shannon | 22 |
| Patrick Baeuerle | 19 |
| Peter Maag | 18 |
| Jean-Jacques Garaud | 17 |
| Michele Galen | 17 |
| Anders Martin-Löf | 16 |
| Bedi Singh | 14 |
| Morana Jovan-Embiricos | 14 |
| Clare Ozawa | 14 |
- Bourse
- Insiders
- Corinne Savill
- Connexions Sociétés
